» Articles » PMID: 16818285

Estimation of Bulky Lymph Nodes by Power Doppler Ultrasound Scanning in Patients with Hodgkin's Lymphoma: a Prospective Study

Overview
Journal Haematologica
Specialty Hematology
Date 2006 Jul 5
PMID 16818285
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The accuracy of standard methods in estimating bulky lesions requires validation. We used clinical/computed tomography (CT) evaluation and power Doppler ultrasound (US) to detect bulky disease in 137 consecutive Hodgkin's lymphoma patients, and analyzed the prognostic relevance of each method. Bulky disease was detected by clinical/CT evaluation in 47% of the patients and by power Doppler US in 20%. After treatment, at multivariate analysis power Doppler US-selected bulky disease was the parameter that best correlated with freedom from treatment failure (p<0.001). Power Doppler US, a readily available imaging technique, provides a better prognostic classification by detecting true bulky disease more accurately.

Citing Articles

A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study.

Lin Y, Sun Y, Li C, Zhang Y, Zhang R, Wang S Ann Hematol. 2025; .

PMID: 40087153 DOI: 10.1007/s00277-025-06299-w.


Lymph Node Ultrasound in Lymphoproliferative Disorders: Where Are We Now?.

Tavarozzi R, Manzato E, Lombardi A J Clin Imaging Sci. 2021; 11:22.

PMID: 33948338 PMC: 8088481. DOI: 10.25259/JCIS_31_2021.


PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.

Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C Ann Hematol. 2021; 100(6):1525-1535.

PMID: 33909101 PMC: 8116299. DOI: 10.1007/s00277-021-04537-5.


Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma.

Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Zeppa P Ann Hematol. 2017; 96(4):627-637.

PMID: 28130574 PMC: 5334396. DOI: 10.1007/s00277-017-2926-9.


Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Flinn I, Kahl B, Leonard J, Furman R, Brown J, Byrd J Blood. 2014; 123(22):3406-13.

PMID: 24615776 PMC: 4260978. DOI: 10.1182/blood-2013-11-538546.